


## Enpp-1-IN-19

<b>Cat. No.:</b>	HY-155457		
<b>CAS No.:</b>	2738583-25-8		
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>16</sub> N <sub>4</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	344.39		
<b>Target:</b>	Phosphodiesterase (PDE); STING		
<b>Pathway:</b>	Metabolic Enzyme/Protease; Immunology/Inflammation		
<b>Storage:</b>	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 125 mg/mL (362.96 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.9037 mL	14.5184 mL	29.0368 mL
	5 mM	0.5807 mL	2.9037 mL	5.8074 mL
	10 mM	0.2904 mL	1.4518 mL	2.9037 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Enpp-1-IN-19 (compound 29f) is an orally active ENPP1 inhibitor that inhibits cGAMP hydrolysis by ENPP1 (IC<sub>50</sub>=68 nM). Enpp-1-IN-19 increases anti-PD-L1 responses and inhibits tumor growth in CT26 syngeneic models. Enpp-1-IN-19 also enhances STING-mediated type I interferon responses, induces immune memory, and prevents tumor recurrence<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

ENPP1<sup>[1]</sup>

### REFERENCES

[1]. Cho Y et al. Discovery of Orally Bioavailable Phthalazinone Analogues as an ENPP1 Inhibitor for STING-Mediated Cancer Immunotherapy. J Med Chem. 2023 Nov 23;66(22):15141-15170.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA